Biotech · Private company · Princeton, NJ, US
Amicus Therapeutics, Inc.
SEC CIK 0001178879
Track this companyFree. Adds Amicus Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials237 recruiting or active
Pipeline programs24From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline24
- Alglucosidase AlfaPhase 3 · Pompe Disease (Late-onset)ClinicalTrials.gov · fetched Nov 12, 2026
- AT2221Phase 3 · Pompe Disease (Late-onset)ClinicalTrials.gov · fetched Nov 12, 2026
- ATB200Phase 3 · Pompe Disease (Late-onset)ClinicalTrials.gov · fetched Nov 12, 2026
- Cipaglucosidase alfaPhase 3 · Glycogen Storage Disease Type II Infantile OnsetClinicalTrials.gov · fetched Nov 12, 2026
- Cipaglucosidase AlfaPhase 3 · Pompe Disease (Late-onset)ClinicalTrials.gov · fetched Nov 12, 2026
- migalastat HCl 150 mgPhase 3 · Fabry DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Migalastat HCl 20 mgPhase 3 · Fabry DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- MiglustatPhase 3 · Pompe Disease (Late-onset)ClinicalTrials.gov · fetched Nov 12, 2026
- MiglustatPhase 3 · Glycogen Storage Disease Type II Infantile OnsetClinicalTrials.gov · fetched Nov 12, 2026
- AT2221Phase 2 · Pompe DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ATB200Phase 2 · Pompe DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- DuvoglustatPhase 2 · Pompe DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- rhGAAPhase 2 · Pompe DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Alglucosidase alfa or Avalglucosidase alfaPompe DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- AT2221Pompe Disease Infantile-OnsetClinicalTrials.gov · fetched Nov 12, 2026
- ATB200Pompe Disease Infantile-OnsetClinicalTrials.gov · fetched Nov 12, 2026
- Cipaglucosidase alfaPompe DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Enzyme Replacement Therapy (ERT)Fabry DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ERTFabry DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- migalastatFabry DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- migalastat HClFabry DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- MiglustatPompe DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- This is a non-interventional studyFabry DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- UntreatedPompe DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials23
- A Study of Patients With Fabry Disease (US Specific)RECRUITING · started Feb 13, 2026ClinicalTrials.gov NCT06906367 · fetched Nov 12, 2026
- A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA VariantsPHASE3 · RECRUITING · started Jan 8, 2026ClinicalTrials.gov NCT06904261 · fetched Nov 12, 2026
- A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and BreastfeedingRECRUITING · started Mar 18, 2025ClinicalTrials.gov NCT04252066 · fetched Nov 12, 2026
- A Global Prospective Observational Registry of Patients With Pompe DiseaseRECRUITING · started Feb 16, 2024ClinicalTrials.gov NCT06121011 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18PHASE3 · RECRUITING · started Jul 18, 2023ClinicalTrials.gov NCT04808505 · fetched Nov 12, 2026
- Understanding Fabry Disease Therapy Choices Through the Eyes of the PatientsCOMPLETED · started Mar 1, 2023ClinicalTrials.gov NCT04804566 · fetched Nov 12, 2026
- A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal DiseasePHASE3 · ACTIVE_NOT_RECRUITING · started Oct 31, 2022ClinicalTrials.gov NCT04020055 · fetched Nov 12, 2026
- A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.COMPLETED · started Mar 1, 2020ClinicalTrials.gov NCT04281537 · fetched Nov 12, 2026
- ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPDPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 13, 2020ClinicalTrials.gov NCT03911505 · fetched Nov 12, 2026
- A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)PHASE3 · COMPLETED · started Dec 18, 2019ClinicalTrials.gov NCT04138277 · fetched Nov 12, 2026
- Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry DiseasePHASE3 · COMPLETED · started Oct 11, 2019ClinicalTrials.gov NCT04049760 · fetched Nov 12, 2026
- A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe DiseasePHASE3 · COMPLETED · started Dec 4, 2018ClinicalTrials.gov NCT03729362 · fetched Nov 12, 2026
- Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)PHASE3 · COMPLETED · started Sep 27, 2018ClinicalTrials.gov NCT03500094 · fetched Nov 12, 2026
- STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERTTERMINATED · started Dec 8, 2017ClinicalTrials.gov NCT03347253 · fetched Nov 12, 2026
- First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221PHASE1_PHASE2 · COMPLETED · started Apr 1, 2016ClinicalTrials.gov NCT02675465 · fetched Nov 12, 2026
- Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis BullosaPHASE3 · TERMINATED · started Jun 9, 2015ClinicalTrials.gov NCT02670330 · fetched Nov 12, 2026
- Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry DiseasePHASE3 · COMPLETED · started Mar 14, 2015ClinicalTrials.gov NCT02194985 · fetched Nov 12, 2026
- ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis BullosaPHASE3 · COMPLETED · started Mar 11, 2015ClinicalTrials.gov NCT02384460 · fetched Nov 12, 2026
- Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis BullosaPHASE2 · TERMINATED · started Mar 26, 2014ClinicalTrials.gov NCT02090283 · fetched Nov 12, 2026
- Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis BullosaPHASE2 · COMPLETED · started Jan 6, 2014ClinicalTrials.gov NCT02014376 · fetched Nov 12, 2026
- Drug-drug Interaction StudyPHASE2 · COMPLETED · started Oct 31, 2011ClinicalTrials.gov NCT01380743 · fetched Nov 12, 2026
- Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe DiseasePHASE2 · TERMINATED · started Dec 8, 2008ClinicalTrials.gov NCT00688597 · fetched Nov 12, 2026
- Expanded Access for ATB200/AT2221 for the Treatment of IOPDAVAILABLEClinicalTrials.gov NCT04327973 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Apr 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 23, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Mar 3, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 20, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Feb 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 26, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 19, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 4, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 4, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Jul 31, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 31, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 5, 2025 · fetched Nov 12, 2026